More recently, ADCs targeting HER2 (among other molecules), such as trastuzumab emtansine, trastuzumab duocarmazine, and disitamab vedotin, showed promising results in multi-tumor basket clinical trials; a further such agent with an enhanced pharmacokinetic profile, namely trastuzumab deruxtecan, is currently under evaluation [16]. This evidence concerns the gene ERBB2 and neoplasm.